Immetas uncovers and creates innovative treatments that regulate the innate immune system for the purpose of addressing age-related cancers and inflammatory ailments. The company’s methodology is rooted in emerging research indicating that persistent low-level inflammation plays a crucial role in the aging process and age-related conditions, and is supported by clinical findings aimed at reducing developmental risk. Immetas was established by J. Gene Wang, MD, PhD, an experienced figure in the field of immunology, inflammation, and oncology drug discovery and translational development, and David Sinclair, PhD, a respected Genetics Professor at Harvard Medical School known for his contributions to understanding the molecular mechanisms of aging.